Diffuse large B‐cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era

Summary The addition of rituximab has improved outcomes in diffuse large B‐cell lymphoma (DLBCL), however, there remains limited information on the impact of rituximab in those with testicular involvement. All patients with diffuse large cell lymphoma and testicular involvement treated with curative...

Full description

Saved in:
Bibliographic Details
Published in:British journal of haematology 2017-01, Vol.176 (2), p.210-221
Main Authors: Kridel, Robert, Telio, David, Villa, Diego, Sehn, Laurie H., Gerrie, Alina S., Shenkier, Tamara, Klasa, Richard, Slack, Graham W., Tan, King, Gascoyne, Randy D., Connors, Joseph M., Savage, Kerry J.
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
B-cell lymphoma
British Columbia
Cancer
Central nervous system
Central Nervous System Neoplasms - prevention & control
Central Nervous System Neoplasms - secondary
central nervous system relapse
Chemotherapy
Cyclophosphamide
Cyclophosphamide - therapeutic use
Databases, Factual
Disease-Free Survival
Doxorubicin
Doxorubicin - therapeutic use
Health risks
Hematology
Humans
Immunotherapy
Incidence
Lymphocytes B
Lymphoma
Lymphoma, Large B-Cell, Diffuse - pathology
Male
Middle Aged
Monoclonal antibodies
Multivariate analysis
Pre-Exposure Prophylaxis - trends
Prednisone
Prednisone - therapeutic use
Prognosis
Prophylaxis
Recurrence
Risk
Rituximab
Rituximab - pharmacology
Rituximab - therapeutic use
Survival
Survival Rate
Targeted cancer therapy
Testes
testicular diffuse large B‐cell lymphoma
Testicular Neoplasms - pathology
Treatment Outcome
Vincristine
Vincristine - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary The addition of rituximab has improved outcomes in diffuse large B‐cell lymphoma (DLBCL), however, there remains limited information on the impact of rituximab in those with testicular involvement. All patients with diffuse large cell lymphoma and testicular involvement treated with curative intent were identified in the British Columbia Cancer Agency Lymphoid Cancer Database. In total, 134 patients diagnosed between 1982 and 2015 with diffuse large cell lymphoma involving the testis were identified: 61 received CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)‐like chemotherapy and 73 received CHOP plus rituximab (R‐CHOP). A greater proportion of R‐CHOP treated patients had higher International Prognostic Index (IPI, P = 0·005). In multivariate analysis, the protective effect of rituximab on progression‐free survival (hazard ratio (HR) 0·42, P 
ISSN:0007-1048
1365-2141
DOI:10.1111/bjh.14392